Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOCANO: Nivolumab as Neoadjuvant Immunotherapy for Patients With Oral CANcer
NCT07514767Phase 2Not yet recruiting
- Start
- May 2026
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in oral squamous cell carcinoma (OSCC). Primary endpoints: Frequency of response up to 4 weeks, Frequency of pathological response up to 4 weeks and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT07514767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07514767.